The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
Highlights
The global IDO Inhibitors market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
Indoleamine-2,3-dioxygenase (IDO) is one of the many immune checkpoints in tumor immune escape. Inhibiting IDO will help researchers restore immune system responses, which in turn, will help identify and destroy cancer cells. In addition to transforming the approach to treat advanced melanoma, the successful entry of IDO inhibitors in the market will also help transform the treatment of non-small lung cancer, triple-negative breast cancer, and bladder cancer with the existing therapies. Currently, most of the IDO inhibitors under investigation are in the very nascent development stage and focusing on R&D, pharmaceutical companies are making huge investments through collaboration agreements. For instance, one of the major pharmaceutical companies Pfizer has partnered with iTeos Therapeutics for the development of undisclosed IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors.
Report Scope
This report aims to provide a comprehensive presentation of the global market for IDO Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IDO Inhibitors.
The IDO Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global IDO Inhibitors market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the IDO Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
Segment by Type
Dual IDO1/TDO inhibitors
Covalent IDO inhibitors
Segment by Application
Metastatic Melanoma
Metastatic Pancreatic Cancer
mCRPC
Malignant Glioma
Astrocytoma
Breast Cancer
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of IDO Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of IDO Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 IDO Inhibitors 麻豆原创 Overview
1.1 Product Overview and Scope of IDO Inhibitors
1.2 IDO Inhibitors Segment by Type
1.2.1 Global IDO Inhibitors 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Dual IDO1/TDO inhibitors
1.2.3 Covalent IDO inhibitors
1.3 IDO Inhibitors Segment by Application
1.3.1 Global IDO Inhibitors 麻豆原创 Value by Application: (2023-2029)
1.3.2 Metastatic Melanoma
1.3.3 Metastatic Pancreatic Cancer
1.3.4 mCRPC
1.3.5 Malignant Glioma
1.3.6 Astrocytoma
1.3.7 Breast Cancer
1.4 Global IDO Inhibitors 麻豆原创 Size Estimates and Forecasts
1.4.1 Global IDO Inhibitors Revenue 2018-2029
1.4.2 Global IDO Inhibitors Sales 2018-2029
1.4.3 Global IDO Inhibitors 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 IDO Inhibitors 麻豆原创 Competition by Manufacturers
2.1 Global IDO Inhibitors Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global IDO Inhibitors Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global IDO Inhibitors Average Price by Manufacturers (2018-2023)
2.4 Global IDO Inhibitors Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of IDO Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of IDO Inhibitors, Product Type & Application
2.7 IDO Inhibitors 麻豆原创 Competitive Situation and Trends
2.7.1 IDO Inhibitors 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest IDO Inhibitors Players 麻豆原创 Share by Revenue
2.7.3 Global IDO Inhibitors 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 IDO Inhibitors Retrospective 麻豆原创 Scenario by Region
3.1 Global IDO Inhibitors 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global IDO Inhibitors Global IDO Inhibitors Sales by Region: 2018-2029
3.2.1 Global IDO Inhibitors Sales by Region: 2018-2023
3.2.2 Global IDO Inhibitors Sales by Region: 2024-2029
3.3 Global IDO Inhibitors Global IDO Inhibitors Revenue by Region: 2018-2029
3.3.1 Global IDO Inhibitors Revenue by Region: 2018-2023
3.3.2 Global IDO Inhibitors Revenue by Region: 2024-2029
3.4 North America IDO Inhibitors 麻豆原创 Facts & Figures by Country
3.4.1 North America IDO Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America IDO Inhibitors Sales by Country (2018-2029)
3.4.3 North America IDO Inhibitors Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe IDO Inhibitors 麻豆原创 Facts & Figures by Country
3.5.1 Europe IDO Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe IDO Inhibitors Sales by Country (2018-2029)
3.5.3 Europe IDO Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific IDO Inhibitors 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific IDO Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific IDO Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific IDO Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America IDO Inhibitors 麻豆原创 Facts & Figures by Country
3.7.1 Latin America IDO Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America IDO Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America IDO Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa IDO Inhibitors 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa IDO Inhibitors 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa IDO Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa IDO Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global IDO Inhibitors Sales by Type (2018-2029)
4.1.1 Global IDO Inhibitors Sales by Type (2018-2023)
4.1.2 Global IDO Inhibitors Sales by Type (2024-2029)
4.1.3 Global IDO Inhibitors Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global IDO Inhibitors Revenue by Type (2018-2029)
4.2.1 Global IDO Inhibitors Revenue by Type (2018-2023)
4.2.2 Global IDO Inhibitors Revenue by Type (2024-2029)
4.2.3 Global IDO Inhibitors Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global IDO Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global IDO Inhibitors Sales by Application (2018-2029)
5.1.1 Global IDO Inhibitors Sales by Application (2018-2023)
5.1.2 Global IDO Inhibitors Sales by Application (2024-2029)
5.1.3 Global IDO Inhibitors Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global IDO Inhibitors Revenue by Application (2018-2029)
5.2.1 Global IDO Inhibitors Revenue by Application (2018-2023)
5.2.2 Global IDO Inhibitors Revenue by Application (2024-2029)
5.2.3 Global IDO Inhibitors Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global IDO Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer IDO Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer IDO Inhibitors Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Corporation Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb IDO Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bristol-Myers Squibb IDO Inhibitors Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Kyowa Hakko Kirin
6.3.1 Kyowa Hakko Kirin Corporation Information
6.3.2 Kyowa Hakko Kirin Description and Business Overview
6.3.3 Kyowa Hakko Kirin IDO Inhibitors Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Kyowa Hakko Kirin IDO Inhibitors Product Portfolio
6.3.5 Kyowa Hakko Kirin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 IDO Inhibitors Industry Chain Analysis
7.2 IDO Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 IDO Inhibitors Production Mode & Process
7.4 IDO Inhibitors Sales and 麻豆原创ing
7.4.1 IDO Inhibitors Sales Channels
7.4.2 IDO Inhibitors Distributors
7.5 IDO Inhibitors Customers
8 IDO Inhibitors 麻豆原创 Dynamics
8.1 IDO Inhibitors Industry Trends
8.2 IDO Inhibitors 麻豆原创 Drivers
8.3 IDO Inhibitors 麻豆原创 Challenges
8.4 IDO Inhibitors 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
Bristol-Myers Squibb
Kyowa Hakko Kirin
听
听
*If Applicable.